AstraZeneca reports benralizumab eliminates oral corticosteroid (OCS) use in majority of oral corticosteroid dependent patients with asthma in PONENTE phase IIIb trial

Trial (n~600) showed for 1st primary endpoint (PE), 62% patients achieved complete elimination of daily OCS use, and on 2nd PE, 81% achieved complete elimination or were able to reduce daily OCS dose to ≤5mg when further reduction was not possible due to adrenal insufficiency.

Source:

Biospace Inc.